Filing Flows › Ironwood Pharmaceuticals (IRWD) › Guidance & outlook
Ironwood Pharmaceuticals (IRWD) guidance and outlook
Ironwood Pharmaceuticals (IRWD) raised its guidance on Nov 5, 2026: Revenue $485M–$510M for FY2026; EBITDA $350M for FY2026; Revenue $460M–$485M for FY2026. Ironwood Pharmaceuticals' 10-Q filed Nov 5, 2026 makes 18 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $1.2B | new |
| Revenue | FY2026 | +35% | new |
| Revenue | FY2026 | $485M–$510M | raised |
| EBITDA | FY2026 | $350M | raised |
| Revenue | FY2026 | $460M–$485M | raised |
From the earnings release filed Nov 5, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 5, 2026
- Subject to the results of STARS-2, we plan to file for regulatory approval in 2029.
- We are unable to predict the extent of any future losses or guarantee that our company will be able to generate and maintain positive cash flows.
- Although we expect net sales to increase over time, the settlement payments between AbbVie and us, resulting in collaborative arrangements revenue or collaboration expense, are subject to fluctuation based on the ratio of selling, general and administrative expenses incurred by each party.
- Through a collaboration and license option agreement, or the COUR Collaboration Agreement, we and COUR Pharmaceutical Development Company, Inc., or COUR, were developing CNP-104 for the treatment of primary biliary cholangitis, or PBC, a rare autoimmune disease targeting the liver.
- We cannot currently estimate with any degree of certainty the amount of time or money that we will be required to expend in the future on linaclotide for additional indications, populations or formulations.
- As a result of these uncertainties surrounding the timing and outcome of any approvals, we are currently unable to estimate precisely when, if ever, linaclotide’s utility will be expanded within its currently approved indications; if or when linaclotide will be developed outside of its current markets, indications, populations or formulations; or when, if ever, apraglutide or any of our other product candidates…
- In addition, we intend to access externally discovered drug candidates that fit within our core strategy.
- We anticipate that we will make determinations as to which additional programs to pursue and how much funding to direct to each program on an ongoing basis in response to the data of each product candidate, the competitive landscape and ongoing assessments of such product candidate’s commercial potential.
- We expect to invest in our development programs and incur substantial research and development expenses for the foreseeable future.
- We will continue to invest in linaclotide, including the investigation of ways to enhance the clinical profile within its currently approved indications, and the exploration of its potential utility in other indications, populations and formulations, and in apraglutide, as we advance it through clinical trials, in addition to funding research and development activities under our external collaboration and license…
- As we continue to invest in the development and commercialization of LINZESS, apraglutide and other product candidates, we expect our selling, general and administrative expenses will be substantial for the foreseeable future.
- Due to our ability to utilize our net operating losses and research and development credits to offset the majority of federal taxable income and taxable income in certain states, the majority of our tax provision will be a non-cash expense.
Ironwood Pharmaceuticals' latest quarter
Ironwood Pharmaceuticals, Q3 2026: revenue $133M (+9% year over year), operating margin 70.0%, net earnings $59.8M, operating cash flow $67.4M. The chart follows the revenue to costs, profit and cash.
Questions
Did Ironwood Pharmaceuticals raise or lower its guidance?
Ironwood Pharmaceuticals (IRWD) raised its guidance on Nov 5, 2026: Revenue $485M–$510M for FY2026; EBITDA $350M for FY2026; Revenue $460M–$485M for FY2026.
What does Ironwood Pharmaceuticals expect?
Subject to the results of STARS-2, we plan to file for regulatory approval in 2029. We are unable to predict the extent of any future losses or guarantee that our company will be able to generate and maintain positive cash flows. Although we expect net sales to increase over time, the settlement payments between AbbVie and us, resulting in collaborative arrangements revenue or collaboration expense, are subject to fluctuation based on the ratio of selling, general and administrative expenses incurred by each party.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.